BeeCure closes $1M pre-seed for honey-based skincare
What's the deal? SanMelix LaboratoriesDealroom has a profile for this one. Try Dealroom →, parent company of skincare brand BeeCureDealroom has a profile for this one. Try Dealroom →, has closed a $1 million pre-seed round, with Capital Q VenturesDealroom has a profile for this one. Try Dealroom → completing the financing as its final investor. The Hollywood, Florida company develops skin and wound care products built on proprietary buckwheat honey-based formulations.
What's the endgame? BeeCure's products are formulated to soothe and hydrate skin affected by radiation and laser treatments, with a pipeline aimed at advanced wound care. The company also maintains a development pipeline for additional applications.
What's the money for? Proceeds are earmarked for commercialisation — expanded sales and distribution, marketing, product development, and operational resources. "With this funding and the continued support of Capital Q Ventures, we are focused on advancing our commercialization strategy," said Steve Weinstein, chief executive officer of BeeCure.
Why now? The round caps a longer fundraising effort. Capital Q had announced a $250,000 investment in March 2025, and a January 2026 investor presentation described a larger raise still underway, making this close the more concrete milestone.
What could go wrong? BeeCure targets a real supportive-care need, but established wound-care and skincare products already serve the space. That makes clinical evidence and distribution more consequential than a modest raise.
The signal: At $1 million, this is a small, early-stage financing rather than a sector-shaping deal. It marks a step toward scaling BeeCure, but it does not by itself point to a broader shift in oncology-care investment.
Read more: einpresswire.com
Image credit: Generated with Gemini
